Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Breast Cancer Research

Fig. 4

From: Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer

Fig. 4

Receptor interactions with ERBB2. a Western blotting showing the co-immunoprecipitation of the indicated receptors with ERBB2 from BT474 cells and AU565 cells. Each line was treated with pertuzumab (100 nM) for the time period indicated, and immunoprecipitation was performed with either a mouse IgG control or ERBB2 monoclonal antibody. Blots are representative of three experiments. b Confocal fluorescence microscopy imaging of proximity mediated ligation assays showing the interaction between ERBB2 and the indicated RTKs in BT474 and AU565 cells (scale bar = 25 μm)

Back to article page